Asked by: Mike Penning (Conservative - Hemel Hempstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care when he plans to reply to the correspondence from the hon. Member for Hemel Hempstead of 11 November 2021, case number MP72424, on providing proof of covid booster vaccination.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We replied to the Rt hon. Member on 22 February 2022.
Asked by: Mike Penning (Conservative - Hemel Hempstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to reply to the correspondence from the hon. Member for Hemel Hempstead of 11 October 2021, case number MP71917 on the loss of jobs at the MHRA.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We replied to the Rt hon. Member on 21 February 2022.
Asked by: Mike Penning (Conservative - Hemel Hempstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to reply to correspondence from the hon. Member for Hemel Hempstead dated 12 August 2021, case number MP 71131 on NHS Staffing Levels.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We replied to the Rt Hon. Member on 5 January 2022.
Asked by: Mike Penning (Conservative - Hemel Hempstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to introduce primary legislation to reform the Mental Health Act 1983 during the current session of Parliament; and if he will ensure that the needs of children and young people are central to any such legislation.
Answered by Gillian Keegan - Secretary of State for Education
Legislation to reform the Mental Health Act 1983 will be brought forward when parliamentary time allows. The reforms will ensure that people of all ages, including children and young people, are put at the centre of decisions about their own care and that everyone is treated equally.
Asked by: Mike Penning (Conservative - Hemel Hempstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that prophylactic use of synthetic monoclonal antibody treatments are available where immunosuppressed patients are not able to suspend their immunosuppressant medication or have not responded to a third primary covid-19 vaccine dose.
Answered by Maggie Throup
Ronapreve (casirivimab and imdevimab) is the first neutralising monoclonal antibody to receive marketing authorisation from the Medicines and Healthcare products Regulatory Agency to treat and prevent COVID-19. The interim clinical policy was updated on 4 November to expand treatment access to a wider group of hospitalised patients, which may include immunocompromised patients. The current supply of Ronapreve is limited globally and the clinical policy prioritises the most vulnerable patients for whom this treatment will have the largest beneficial impact.
The RAPID C-19 collaboration has enabled active multi-agency oversight of national and international trial evidence as it emerges for COVID-19 therapies, both in potential treatment and prophylactic indications. Where material evidence is identified, this has enabled the rapid formation and implementation of United Kingdom wide clinical access policies. To date, the evidence has most strongly supported treatment indications, but the evidence around prophylactic use will continue to be actively reviewed.
Asked by: Mike Penning (Conservative - Hemel Hempstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure immunosuppressed patients are aware that they may be able to suspend their immunosuppressant medication in order to obtain a third primary covid-19 vaccine dose.
Answered by Maggie Throup
The Government regularly provides resources and additional information to charities and patient organisations representing those living with severely compromised immune systems. NHS England and NHS Improvement are developing tailored communications for specialists caring for each group of eligible patients within the immunosuppressed cohort. This will include template referral letters for clinicians to signpost people to receive their vaccination.
Any decision to defer immunosuppressive therapy or to delay the possible benefit from vaccination until after therapy should be taken by the specialist. These decisions should not be taken without due consideration to the risks from COVID-19 and from their underlying condition.
Asked by: Mike Penning (Conservative - Hemel Hempstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to provide post-vaccination quantitative antibody testing for immunocompromised patients.
Answered by Maggie Throup
National Health Service clinicians can arrange antibody testing based on their assessment of clinical need. There are currently no plans to implement targeted quantitative antibody testing for immunocompromised patients post-vaccination.
Those with a cancer diagnosis may be able to access free antibody tests through the National Cancer COVID Survey which aims to assess levels of protection conferred by antibodies following vaccination/infection in cancer patients. The Joint Committee on Vaccination and Immunisation continues to review emerging scientific evidence on the use of vaccines in those who are immunocompromised and will update its advice as necessary.
Asked by: Mike Penning (Conservative - Hemel Hempstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to reply to correspondence from the hon. Member for Hemel Hempstead of 12 August 2021, case no. MP70336, departmental reference PO-1342263, on covid-19 vaccinations for immunocompromised patients.
Answered by Edward Argar - Minister of State (Ministry of Justice)
We replied to the Rt hon. Member on 3 December 2021.
Asked by: Mike Penning (Conservative - Hemel Hempstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 October 2021 to Question 58780, on Fibrodysplasia Ossificans Progressiva: Research, if he will provide details of the eight studies into fibrodysplasia ossificans progressive (FOP) supported by funding through the National Institute for Health Research.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The titles of seven of the studies supported by the National Institute for Health Research on fibrodysplasia ossificans progressiva (FOP) are as follows:
- Saracatinib Trial TO Prevent FOP (Fibrodysplasia Ossificans Progressiva);
- Isolation and Generation of Blood-derived Progenitor Cells from Patients with Cardiovascular Disease and TGF-beta Superfamily-related Diseases;
- A Phase 2 Randomized, Double Blind, Placebo Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flareups in Subjects with Fibrodysplasia Ossificans Progressiva;
- A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva;
- A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progressiva;
- A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva; and
- A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of two dosage regimens of oral IPN60130 for the treatment of fibrodysplasia ossificans progressiva in male and female participants five years of age and older.
We are unable to provide details of the remaining study as this information is commercially sensitive.
Asked by: Mike Penning (Conservative - Hemel Hempstead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what level of funding his Department is providing for research into (a) slowing the symptoms of and (b) finding a cure for fibrodysplasia ossificans progressiva.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
I refer the Rt hon. Member to the answer I gave on 22 October 2021 to Question 58780.